NEW YORK--(BUSINESS WIRE)--

Signal Genetics, a privately held cancer genetics testing company, today announced the launch of its new physician portal and analysis tool, ResultsPX. The Health Insurance Portability and Accountability Act (HIPAA) compliant web portal will enhance physicians ability to administer and analyze the results of Signal Genetics predictive genomic tests, including MyPRS PlusTM for multiple myeloma and PrevistageTM GCC for colon cancer staging and recurrence.

Signal Genetics physician customers can use ResultsPX to retrieve the results of tests performed by Signal Genetics at its CLIA certified laboratories, and to conduct their own, deeper analysis of their patients genomic profile to better inform treatment decisions. The portal will initially be available to physicians that order Signal Genetics genomic tests, as well as select hospitals in Europe.

Our ResultsPX web portal combines state-of-the-art genomic science and technology to produce interactive, exhaustive genomic data analysis to physicians globally. We believe putting more information in the hands of physicians will enable them to make the most informed decisions for their patients, said Joe Hernandez, President and CEO of Signal Genetics. This innovative and secure technology is a key complement to our assays, and makes our strong portfolio of predictive molecular diagnostic tests for various cancers even more accessible. The portal is completely scalable, and will also support each of our genomic tests in development upon launch, including our products in development for breast cancer and lung cancer.

ResultsPX will also enable remote interpretation of Signal Genetics test algorithms in a secure and controlled environment. In Europe, where testing is typically done in internal hospital laboratories, physicians will be able to run Signal Genetics assays on-site with ResultsPX, eliminating the need to ship patient samples to labs. The portals unique technology and strict quality control standards will allow hospitals to receive accurate test results within minutes.

For more information, please visit: http://www.SignalGenetics.com

About Signal Genetics

Signal Genetics, the parent company of Myeloma Health LLC, CC Health, Respira Health, and ChipDX, is a privately held predictive genetic testing company focused on helping cancer patients. MyPRS Plus stratifies risk for patients with multiple myeloma and provides additional insights in to the genetic characteristics of each individual patient. PrevistageTM GCC Colorectal Cancer Staging Test currently is the only colorectal cancer staging test on the market that provides prognostic information based on the tumor burden measured at the molecular level in the lymph nodes. The goal of Signal Genetics is to provide cancer patients and their physicians with novel and innovative insights into their disease, including predicting outcomes, accurately staging disease, providing odds of relapse, and identifying the optimal treatment regimen based on their specific genetic profile. Additional information is available at http://www.signalgenetics.com

Link:
Signal Genetics Announces Launch of New Physician Web Portal and Genetic Test Results Analysis Tool

Comments are closed.